Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase

Stock Track

03/26

Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.

The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.

Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1100707834"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100707834\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100707834?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100707834","market":"hk","top_or_hot":-1,"title":"Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase","media":"Stock Track","content":"<p>Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.</p><p>The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.</p><p>Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Peijia Medical Soars 5.28% Intraday on Strong FY2025 Results, Regulatory Approval, and CEO Share Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-26 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.</p><p>The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.</p><p>Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09996","symbol_name":"沛嘉医疗-B","start_time":0,"source_url":"","article_id":"1100707834","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100707834","pubTimestamp":1774490141,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09996":"沛嘉医疗-B"},"translate_title":"个股赛道|沛嘉医疗盘中大涨5.28%，得益于强劲的2025财年业绩、监管批准、CEO购股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"Peijia Medical's stock surged 5.28% during intraday trading on Thursday. The significant upward movement followed the release of the company's robust annual financial results and positive corporate developments.The medical device company reported a 15.8% increase in FY2025 revenue to RMB 713 million, with the neurointerventional business segment profit jumping 86.6% to RMB 97 million. Furthermore, the company received National Medical Products Administration (NMPA) approval for its TaurusTrio® TAV system to treat symptomatic severe aortic regurgitation, expanding its commercial addressable market in China.Adding to investor confidence, the company announced that its Executive Director, CEO, and Board Chair, Yi Zhang, plans to increase his stake through a controlled corporation with purchases capped at HKD 15 million. The company also indicated that 2026 is expected to represent an initial stage of its global expansion in the neurointerventional business.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}